Olaparib indications

Olaparib is a poly(ADP-ribose polymerase) (PARP) inhibitor. Indications:

1.Ovarian cancer

•For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic diseaseBRCA-Mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Patients are selected for treatment based on FDAapproved olaparib companion diagnostics.

•In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with a positive homologous recombination defect (HRD) status.

•For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somaticBRCA mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy. Patients are selected for treatment based on FDAapproved olaparib companion diagnostics.

2.Breast cancer

•For patients with or suspected of having harmfulg. BRCAPatients with epidermal growth factor receptor 2 (her 2) negative high-risk early breast cancer who have received neoadjuvant or adjuvant chemotherapy. Patients are selected for treatment based on FDAapproved olaparib companion diagnostics.

•For the treatment of adult patients with deleterious or suspected deleterious diseasegBRCA who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic settingm, HER2patients with negative metastatic breast cancer. Patients with hormone receptor (HR)-positive breast cancer should have previously received endocrine therapy or be considered unsuitable for endocrine therapy. Patients are selected for treatment based on FDAapproved olaparib companion diagnostics.

3.Pancreatic cancer

•For the maintenance treatment of adult patients with deleterious or suspected deleterious diseasegBRCAmmetastatic pancreatic cancer whose disease has not progressed on at least16 weeks of first-line platinum-based chemotherapy. Patients are selected for treatment based on FDAapproved olaparib companion diagnostics.

4.Prostate cancer

•For the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Patients are selected for treatment based on FDAapproved olaparib companion diagnostics.

•In combination with abiraterone and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleteriousBRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients are selected for treatment based on FDAapproved olaparib companion diagnostics. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0